Fresenius SE & Co. KGaA

OTCPK:FSNU.F Stock Report

Market Cap: US$19.5b

Fresenius SE KGaA Valuation

Is FSNU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FSNU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FSNU.F ($32.16) is trading below our estimate of fair value ($81.34)

Significantly Below Fair Value: FSNU.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FSNU.F?

Key metric: As FSNU.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for FSNU.F. This is calculated by dividing FSNU.F's market cap by their current revenue.
What is FSNU.F's PS Ratio?
PS Ratio0.8x
Sales€22.81b
Market Cap€18.49b

Price to Sales Ratio vs Peers

How does FSNU.F's PS Ratio compare to its peers?

The above table shows the PS ratio for FSNU.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
LH Labcorp Holdings
1.6x4.7%US$19.7b
DGX Quest Diagnostics
1.9x4.9%US$17.9b
DVA DaVita
1x3.5%US$13.1b
CHE Chemed
3.5x6.2%US$8.3b
FSNU.F Fresenius SE KGaA
0.8x3.6%US$18.5b

Price-To-Sales vs Peers: FSNU.F is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does FSNU.F's PS Ratio compare vs other companies in the US Healthcare Industry?

33 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$76.96b
CVS CVS Health
0.2x4.7%US$66.93b
COR Cencora
0.2x6.4%US$47.09b
CNC Centene
0.2x5.6%US$29.01b
FSNU.F 0.8xIndustry Avg. 0.9xNo. of Companies33PS012345+
33 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: FSNU.F is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is FSNU.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FSNU.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate FSNU.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FSNU.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$42.83
0%
11.3%US$53.97US$32.38n/a15
Oct ’25US$37.35
US$43.77
+17.2%
11.1%US$55.54US$33.32n/a15
Sep ’25n/a
US$42.59
0%
12.9%US$55.11US$33.07n/a15
Aug ’25US$34.15
US$41.70
+22.1%
12.9%US$53.95US$32.37n/a15
Jul ’25n/a
US$39.93
0%
14.1%US$53.58US$30.01n/a16
Jun ’25n/a
US$39.88
0%
14.8%US$54.29US$30.41n/a16
May ’25n/a
US$38.85
0%
15.0%US$53.64US$30.04n/a16
Apr ’25n/a
US$39.14
0%
15.0%US$54.03US$30.26n/a16
Mar ’25US$27.98
US$41.29
+47.6%
25.0%US$75.66US$30.26n/a17
Feb ’25US$28.84
US$41.69
+44.6%
24.1%US$75.63US$32.41n/a17
Jan ’25n/a
US$41.88
0%
24.6%US$75.84US$32.50n/a16
Dec ’24US$31.00
US$42.27
+36.3%
25.1%US$76.90US$32.52n/a16
Nov ’24US$25.77
US$40.87
+58.6%
23.7%US$72.17US$31.42n/a16
Oct ’24n/a
US$41.28
0%
24.1%US$72.66US$31.63US$37.3516
Sep ’24US$32.00
US$41.44
+29.5%
24.6%US$74.15US$30.53n/a17
Aug ’24US$32.00
US$40.24
+25.7%
27.5%US$75.87US$29.69US$34.1517
Jul ’24US$26.50
US$39.83
+50.3%
28.6%US$75.48US$28.44n/a16
Jun ’24n/a
US$41.07
0%
41.2%US$98.99US$27.98n/a15
May ’24US$28.02
US$40.70
+45.3%
43.8%US$100.92US$24.13n/a15
Apr ’24US$27.19
US$38.47
+41.5%
46.1%US$98.80US$17.83n/a16
Mar ’24US$27.50
US$37.27
+35.5%
47.6%US$97.33US$17.56US$27.9816
Feb ’24n/a
US$38.62
0%
47.0%US$100.01US$18.05US$28.8416
Jan ’24US$26.94
US$37.23
+38.2%
48.1%US$97.69US$17.63n/a16
Dec ’23US$28.50
US$37.03
+29.9%
48.0%US$95.06US$17.15US$31.0015
Nov ’23n/a
US$35.19
0%
47.0%US$90.87US$16.40US$25.7716

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$29.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$58.83

7D

-3.2%

1Y

-19.1%

Elevance Health

US$92.9b

Operates as a health benefits company in the United States.

ELV

US$400.70

7D

-5.8%

1Y

-13.9%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

7D

0.4%

1Y

-17.9%